

alzchem
group



Q3

2022

ANDREAS NIEDERMAIER, CEO
DR. GEORG WEICHSELBAUMER, CSO

October 26, 2022

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q3 2022

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

HIGHLIGHTS

Successful 9 months – challenging environment



Continuously high sales growth due to successful adjustment of contract prices



EBITDA slightly below previous year level due to power price jumps in Q3

Group result above previous year



Segment Specialty Chemicals grows in quantity, sales and EBITDA



Ongoing strong demand in human nutrition, steel and pharma as well as automotive industry



Equity ratio increased to 31.9%


High net working capital requires short term financing



Launch of expanded Creapure® production scheduled in October

TURBULENT MARKET ENVIRONMENT – CURRENT DEVELOPMENT

Energy costs – facing all time high



COMMENTS

- Average electricity prices jumped twofold in Q3
- Compared to the pre-crisis situation, electricity prices are about 658% higher today
- Alzchem reacted to this development by making use of its flexibility in managing production

➔ This enabled us to prevent the extreme electricity price developments being fully reflected in the figures

Source: EPEX-SPOT Baseload Day Ahead daily average

FINANCIAL OVERVIEW

Sales growth with strong cost pressure



Alzchem Group	Q3 2021	Q3 2022	yoy %	2021 1 - 9	2022 1 - 9	yoy %
SALES (in M€)	95.9	139.2	+45.1%	311.2	409.0	+31.4%
EBITDA (in M€)	13.8	12.1	-12.2%	49.6	47.0	-5.1%
EBITDA margin (in %)	14.4%	8.7%	-5.7pp	15.9%	11.5%	-4.4pp
Earnings per Share (in €)	0.46	0.59	+28.3%	2.15	2.29	+6.5%

- Enormous sales growth due to price increases continues
- Segment Specialty Chemicals is compensating negative quantity effects in Basic & Intermediates
- High electricity prices from July to September impacting the result in Q3 noticeably
- Despite the distortions on the energy market, Specialty Chemicals segment is still on growth course
- Raw material shortages for natural gas-based and electricity-intensive raw materials are getting worse

SALES ANALYSIS	DELTA Q3	DELTA 01 - 09
Volume	1.8%	-0.6%
Price	37.4%	28.8%
Currency	5.8%	3.2%

CREATINE HEALTH CLAIM

In 2012, the European Commission approved an health-related statement (Health Claim) for Creatine:

Creatine increases physical performance in successive bursts of short-term, high intensity exercise.



Short-term

Sports Nutrition: Creatine has performance benefits in various sports disciplines, e.g. soccer



Short-term

Healthy Aging: Creatine helps to slow down the loss of muscle mass for the 50+ generation



Mid-term

Vegetarians: Vegetarians have a lower creatine level on average and would benefit from Creatine intake



Long-term

Functional Food: Creatine has the potential to be used in functional food (e.g. in yoghurt)



Long-term

Pharma: Creatine has been studied in new health applications, e.g. dialysis and COVID



CERTIFICATES




HEALTH BENEFITS



Average adult has around **80 - 130 g** of Creatine in the body



Only ~50% of the daily Creatine requirement is met through food intake



3 g of Creatine per day help to increase body strength and muscle recovery

**DECISION FOR CAPEX
TAKEN IN Q2 2021**

**COMMISSIONING
ALREADY STARTED IN
Q3 2022**



**SPECIALTY
CHEMICALS**

The additional investment will create profitable growth for the segment

~ 13 m€ CAPEX

Regional market penetration

Regional market expansion

Product shortage on the market

New sales products added

New Creapure[®] applications seen in the future
(functional food, Vegetarian nutrition, healthy aging,
health applications)

**ADDITIONAL
DEMAND**

Plant expansion in special equipment and materials

**TURNOVER
POTENTIAL**

Up to 40 m€, dependent on product portfolio

AGENDA – ANALYST PRESENTATION Q3 2022

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES

The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.


alzchem
group 

BASICS & INTERMEDIATES SEGMENT (in M€)




Sales significantly above prior year


SALES




EBITDA



SALES



EBITDA





SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	- 11.2%	- 6.6%
Price	+ 50.8%	+ 41.8%
Currency	+ 0.7%	+ 0.7%

COMMENTS

- Q3/2022 sales significantly above previous year (~40 %)
- Sales within the metallurgic, pharmaceutical as well as agriculture sector significantly above Q3/2021
- Impact from price increases overcompensates decrease in quantity
- Nevertheless, EBITDA is negatively affected by the high cost increases for power supply
- Thus, EBITDA-Margin of -4.4 % in Q3/2022 (previous year +7.3 %)



CREAMINO  **Dormex**[®] **Bioselect**[®] **DYHARD**[®]  **Creapure**[®]

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

SPECIALTY CHEMICALS SEGMENT (in M€)


Encouraging business performance




SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	+ 13.5%	+ 4.2%
Price	+ 30.1%	+ 21.6%
Currency	+ 11.3%	+ 5.6%

COMMENTS

- Sales in Q3/2022 about 55 % above previous year level
- Growth in quantity, sales volume and EBITDA
- Demand for building blocks, automotive sector (Nitroguanadine, DYHARD®) as well as agriculture sector (Dormex®) on a persistent high level
- High sales in human nutrition (Creapure®); capacity expansion will help to fulfill customer requirements
- Positive sales trend visible for BioSelect®
- Despite volatile economic situation, EBITDA-Margin with appr. +21.0 % on a stable level (previous year +23.8 %)



OTHER & HOLDING


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)


Development of services in line with 2021




SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

	DELTA Q3	DELTA 01 - 09
Volume	+ 2.6%	- 0.9%
Price	+ 2.6%	+ 2.6%
Currency	± 0.0%	± 0.0%

COMMENTS


- Q3/2022 sales slightly above previous year's level (~5 %)
- Sales performance supported by higher demand for energy supply and supply chain management
- EBITDA supported by internal efficiency program and lower maintenance in infrastructure

BALANCE SHEET (in M€)

Increase of balance sheet total and equity ratio




ASSETS



- Decrease in non-current assets (+CAPEX/-deferred tax) and an increase in current assets (Net Working Capital)
- The price and availability effects on the raw material and energy side are reflected in the increase of inventories (+45 M€). Distortions on the raw materials markets continue to mean that inventory safeguards are necessary on both the purchasing and sales side.
- Higher sales prices resulted in higher trade receivables
- Deferred tax assets for pension provision decreased following the interest rate increase for pension valuation


LIABILITIES



- Equity ratio increased from 23.7% to 31.9%; strong increase mainly driven by the reduction of pension provision due to higher interest rates in actuarial assumptions (50.2 M€ net of tax); positive result of 23.4 M€ further increased equity
- Dividend payment of 10.1 M€ in May 2022 and deferred taxes of 14 M€ reduced equity on the other side
- Current liabilities increased by 72.0 M€ to finance increase in net working capital; regular loan and lease repayments reduced non-current liabilities
- Increase of trade payables of 16.8 M€ due to higher costs for raw materials and energy

CASHFLOW (in M€)

Net cashflow impacted by NWC management on both directions



- Net cashflow lower than comparative period; while net result has not changed compared to last year, increase in net working capital leads to much higher cash outflows (increase net working capital at 56.8 M€); mainly based on inventory safety stock
- Investing cashflow at 22.2 M€ and 0.5 M€ lower increase than 1-9 2021; some replacement projects have been postponed while we keep on track for our major growth projects (capacity increase Creapure® plant)
- Cash flow for financing activities mirrors development of net working capital; leading to short term financing cash inflows of 57.0 M€
- Regular loan and lease repayments mainly on prior year level with 9.4 M€; dividend payments of 10.1 M€ reduced financing cashflow

IMPLEMENTING OPERATING TARGETS

Focus on the key growth drivers and sustainability



Implementation of price increases, at least in the amount of the cost increases

SUSTAINABILITY

- Set the path to CO₂ neutral growth and climate neutrality by 2045
- Vision 0 accidents
- Vision 0 waste – promoting circular economy
- Introduction of EU Taxonomy Regulation – Taxonomy compliance
- Organize transition from NFRD (Nonfinancial Reporting Directive) to CSRD (Corporate sustainability Reporting Directive)

Realization and commissioning of Creapure® capacity expansion

Continue to grow NITRALZ® and Creamino® business


Management of COVID-19 effects

OUTLOOK 2022 (in M€)


Parity of cost with price increases will determine EBITDA



SALES



EBITDA



COMMENTS

- Adjustment of the upper sales limit (in Q1/2022) from 480 M€ to 520 M€ due to necessary price increases
- Outlook 2022 from May 2022 is still confirmed
- EBITDA-expectation at the lower end of the given corridor
- The Outlook is based on a calming of the development on the electricity markets and an internal forecast of electricity prices
- Price increases will determine EBITDA – balance short term needs with long-term requirements
- On-time commissioning of Creapure® capacities
- The increase in sales will probably not lead to a further increase in EBITDA, due to continued high input costs (raw material, power, logistics) and volatility
- Should these assumptions not materialize in whichever direction, further fluctuations in EBITDA or EBITDA-Margin are possible

FINANCIAL CALENDAR*

Upcoming dates



NOV 15	2022	Münchner Kapitalmarkt Konferenz
NOV 28 – 29	2022	Deutsches Eigenkapitalforum
FEB 28	2023	Annual Report 2022
MAY 4	2023	Quarterly Statement 1st Quarter 2023
MAY 11	2023	Annual General Meeting 2023
AUG 3	2023	Half-Year Financial Report 2023
OCT 26	2023	Quarterly Statement 3rd Quarter 2023

*subject to change

**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q3 2022

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

BALANCE SHEET

Alzchem Group




ALZCHEM GROUP (IN T€)	31.12.2021	30.09.2022	Deviation	
Intangible assets	2,329	2,568	238	10.2%
Tangible assets	178,806	181,018	2,212	1.2%
Investment properties				
Right of use (assets)	7,686	6,424	-1,262	-16.4%
Investments accounted for using the equity				
Financials assets	20	6	-15	-73.1%
Trade receivables				
Other receivables	1,320	1,521	201	15.2%
<i>there of Deferred tax assets for pensions p</i>				
Deferred tax assets	34,924	18,473	-16,452	-47.1%
SUM NON-CURRENT ASSETS	225,086	210,010	-15,077	-6.7%
Inventories	86,676	131,482	44,806	51.7%
Trade receivables	40,841	52,482	11,641	28.5%
Financial assets				
Other receivables	16,454	32,576	16,123	98.0%
Income tax receivables	326	627	301	92.5%
Cash and cash equivalents	8,285	9,506	1,222	14.7%
Assets classified as held for sale				
Other assets				
SUM CURRENT ASSETS	152,581	226,673	74,092	48.6%
SUM ASSETS	377,667	436,683	59,016	15.6%

ALZCHEM GROUP (IN T€)	31.12.2021	30.09.2022	Deviation	
Share capital	101,763	101,763		
RETAINED EARNINGS (+) / LOSS (-)	101,127	114,212	13,085	12.9%
Other comprehensive income	-51,104	-14,643	36,461	-71.3%
Own shares	-1,009	-1,009		
SHARE TO THE SHAREHOLDERS	87,630	137,176	49,546	56.5%
Non-controlling interests	1,934	2,063	128	6.6%
SUM EQUITY	89,565	139,239	49,674	55.5%
Provisions for pensions	140,005	90,249	-49,756	-35.5%
Other provisions	24,372	19,389	-4,984	-20.4%
Loans	37,553	30,011	-7,541	-20.1%
Finance lease liabilities	5,793	4,779	-1,015	-17.5%
Trade liabilities				
Other liabilities	171		-171	-100.0%
Deferred tax liabilities	4,084	4,918	833	20.4%
SUM NON-CURRENT LIABILITIES	211,979	149,346	-62,633	-29.5%
Other provisions	2,968	1,590	-1,379	-46.4%
Loans	10,490	67,041	56,552	539.1%
Finance lease liabilities	1,805	1,697	-108	-6.0%
Finance liabilities				
Trade liabilities	32,780	49,617	16,838	51.4%
Other liabilities	26,220	25,724	-496	-1.9%
Income tax liabilities	1,862	2,429	567	30.5%
SUM CURRENT LIABILITIES	76,124	148,099	71,974	94.5%
Sum EQUITY AND LIABILITIES	377,667	436,683	59,016	15.6%

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Adjustment of market interest rate from 1.0 % → 3.4 %; decreasing impact on provision
- Stable development of expected pension trend at 2.0 %
- Stable development of expected salary trend at 3.0 %
- Moderately increasing cash payments

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Deviation (Q3)	
Revenue	104,321	111,000	95,920	111,052	129,395	140,435	139,193		43,273	45%
Increase (+) / Decrease (-) in inventories of finished goods	-2,144	-1,621	6,350	7,442	14,144	14,467	-1,959		-8,309	-131%
Other income	3,983	2,505	2,143	2,729	4,070	5,736	5,955		3,812	178%
Raw materials and consumables used	-36,226	-37,538	-42,153	-54,753	-73,537	-74,027	-75,308		-33,155	79%
Employee benefits expense	-33,038	-35,209	-30,875	-33,045	-34,000	-36,287	-31,316		-441	1%
Other expense	-20,175	-20,143	-17,548	-20,932	-23,003	-32,517	-24,418		-6,870	39%
EBITDA	16,722	18,993	13,838	12,493	17,070	17,807	12,149		-1,690	-12%
Depreciation expense	-5,771	-5,900	-6,206	-6,598	-6,305	-6,299	-6,324		-118	2%
Impairment										
EBIT	10,951	13,094	7,632	5,895	10,765	11,508	5,825		-1,807	-24%
Investment income										
Other interest and similar income	512	244	139	-252	1,181	2,393	2,466		2,327	>1.000%
Other interest and similar expense	-425	-413	-431	-434	-603	-643	-753		-323	75%
Financial result	88	-169	-292	-686	578	1,750	1,713		2,005	-687%
Result from associates										
Result from ordinary business	11,039	12,924	7,340	5,209	11,343	13,258	7,538		197	3%
Taxes on income and profit	-3,109	-3,710	-2,608	679	-3,603	-3,629	-1,559		1,049	-40%
<i>thereof income tax</i>	-2,737	-3,330	-1,944	-1,036	-2,520	-2,094	-842		1,102	-57%
<i>thereof change from deferred taxes</i>	-373	-380	-663	1,715	-1,082	-1,535	-717		-53	8%
Annual result	7,930	9,214	4,733	5,887	7,740	9,630	5,979		1,246	26%
<i>thereof minority interests</i>	43	43	43	43	43	43	43			
<i>thereof shares held by shareholders</i>	7,887	9,171	4,690	5,844	7,698	9,587	5,936		1,246	27%
Result per share in EUR	0.78 €	0.90 €	0.46 €	0.58 €	0.76 €	0.95 €	0.59 €	- €		

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

Revenue
Increase (+) / Decrease (-) in inventories of finished goods and work in progress
Other income
Raw materials and consumables used
Employee benefits expense
Other expense
EBITDA
Depreciation expense
Impairment
EBIT
Investment income
Other interest and similar income
Other interest and similar expense
Financial result
Result from associates
Result from ordinary business
Taxes on income and profit
<i>thereof income tax</i>
<i>thereof change from deferred taxes</i>
Annual result
<i>thereof minority interests</i>
<i>thereof shares held by shareholders</i>
Result per share in EUR

Q3 2021	Q3 2022	Deviation (QoQ)	
95,920	139,193	43,273	45.1%
6,350	-1,959	-8,309	-130.8%
2,143	5,955	3,812	177.9%
-42,153	-75,308	-33,155	78.7%
-30,875	-31,316	-441	1.4%
-17,548	-24,418	-6,870	39.1%
13,838	12,149	-1,690	-12.2%
-6,206	-6,324	-118	1.9%
0	0	0	
7,632	5,825	-1,807	-23.7%
0	0	0	
139	2,466	2,327	>1.000%
-431	-753	-323	74.9%
-292	1,713	2,005	-686.9%
0	0	0	
7,340	7,538	197	2.7%
-2,608	-1,559	1,049	-40.2%
-1,944	-842	1,102	-56.7%
-663	-717	-53	8.0%
4,733	5,979	1,246	26.3%
43	43	0	0.0%
4,690	5,936	1,246	26.6%
0.46 €	0.59 €	0	28.3%

YTD Sep.2021	YTD Sep.2022	Deviation (YoY)	
311,242	409,023	97,781	31.4%
2,586	26,652	24,067	930.8%
8,631	15,761	7,130	82.6%
-115,918	-222,871	-106,954	92.3%
-99,122	-101,602	-2,481	2.5%
-57,866	-79,938	-22,072	38.1%
49,553	47,025	-2,528	-5.1%
-17,877	-18,927	-1,051	5.9%
0	0	0	
31,677	28,098	-3,579	-11.3%
0	0	0	
895	6,041	5,146	574.7%
-1,269	-1,999	-730	57.6%
-374	4,042	4,415	<-1.000%
0	0	0	
31,303	32,139	836	2.7%
-9,427	-8,790	637	-6.8%
-8,011	-5,456	2,554	-31.9%
-1,416	-3,334	-1,917	135.4%
21,876	23,349	1,473	6.7%
128	128	0	0.0%
21,748	23,221	1,473	6.8%
2.15 €	2.29 €	0	6.5%

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

	Q3 2021	Q3 2022	1 - 9 2021	1 - 9 2022
Consolidated earnings before taxes	7,340	7,538	31,303	32,139
Depreciation on fixed and intangible assets	6,205	6,324	17,877	18,927
Decrease in pension provisions	-325	-375	-1,075	-1,253
Loss (+) / Profit (-) from the sale of non-current assets	-4	0	-10	-58
Other non-cash income (-) and expenses (+)	-395	966	2,157	2,802
Financial result	292	-1,713	374	-4,042
Interests & Taxes	-2,098	-2,406	-6,092	-6,195
Increase (+) / Decrease (-) Net Working Capital	-11,790	-7,263	-19,609	-56,420
Cashflow from ongoing operations (Net cash flow)	-775	3,070	24,926	-14,099
Cash outflows for investments in fixed assets	-5,266	-7,662	-21,680	-22,743
Cash inflows from the sale of fixed assets	4	0	16	61
Cash inflow from the disposal of investments		484		484
Cashflow from investing activity	-5,261	-7,177	-21,665	-22,198
Free cashflow	-6,036	-4,106	3,261	-36,296
Deposits (+) / Repayment (-) bank loans long-term				
Repayment of bank loans long-term	-3,449	-2,514	-9,256	-7,976
Deposits (+) / Repayment (-) from short-term financing lines	6,024	6,294	6,024	56,956
Dividend payments			-7,821	-10,136
Payment of reduction in leasing liabilities	-493	-470	-1,415	-1,411
Payments for the acquisition of own shares (incl. transaction costs)	-3		-1,013	
Payments to non-controlling interests			-171	-171
Cashflow from financing activity	2,080	3,310	-13,651	37,263
Net increase / decrease in cash and cash equivalents	-3,957	-797	-10,390	966

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES

	2020				2021				2022				YTD Q2 2022			
SALES	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Deviation PY (Q3) T€ %		PY T€	Actual T€
Basics & Intermediates	36,012	38,266	32,320	39,837	41,070	45,178	42,465	47,561	57,441	57,927	59,557		17,091	40%	128,713	174,925
Specialty Chemicals	52,199	57,854	42,995	54,383	56,775	59,330	47,116	57,279	65,279	76,214	72,967		25,851	55%	163,220	214,459
Other and Holding	6,529	6,391	6,058	6,414	6,477	6,492	6,339	6,212	6,675	6,294	6,670		331	5%	19,309	19,639
Group Consolidation																
Alzchem Group	94,740	102,511	81,373	100,634	104,321	111,000	95,920	111,052	129,395	140,435	139,193		43,273	45%	311,242	409,023

EBITDA

	2020				2021				2022				YTD Q2 2022			
EBITDA	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Q1 T€	Q2 T€	Q3 T€	Q4 T€	Deviation PY (Q3) T€ %		PY T€	Actual T€
Basics & Intermediates	1,903	2,485	2,006	2,587	2,791	3,826	3,118	1,250	2,841	853	-2,621		-5,739	-184%	9,735	1,073
Specialty Chemicals	10,158	14,457	9,418	10,092	13,947	14,801	10,096	11,820	14,267	16,322	14,637		4,540	45%	38,844	45,225
Other and Holding	317	81	361	230	435	-43	512	502	-139	830	1,038		526	103%	904	1,729
Group Consolidation	-63	-201	202	-227	-451	409	112	-1,079	103	-200	-905		-1,017	-906%	71	-1,002
Alzchem Group	12,315	16,822	11,986	12,683	16,722	18,993	13,838	12,493	17,072	17,805	12,149		-1,690	-12%	49,553	47,025

EXECUTIVE TEAM

Alzchem Group AG



ANDREAS NIEDERMAIER

CEO

WITH ALZCHEM SINCE 1999

AREAS OF RESPONSIBILITY

Company Strategy, Finance & Controlling, Investor Relations & Communication, IT, Risk Management, HR, Supply Chain Management, Legal/Patents & Trademarks

KLAUS ENGLMAIER

COO

WITH ALZCHEM SINCE 1988

AREAS OF RESPONSIBILITY

Production, Engineering, Environment/Safety/Health/Quality, Technology

DR. GEORG WEICHSELBAUMER

CSO

WITH ALZCHEM SINCE 2012

AREAS OF RESPONSIBILITY

Marketing, Sales, Innovation Management & Process Development, R&D, Product Safety and Approval




ALZCHEM GROUP LOCATIONS

Production sites and sales companies



“VERBUND” – FULLY INTEGRATED BUSINESS MODEL

Benefits of the “Verbund” system approach



BENEFITS OF “VERBUND”

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

MEGATRENDS AS GROWTH DRIVERS



POPULATION
GROWTH



LONGER LIFE
EXPECTANCY



CLIMATE
CHANGE



SUSTAINABILITY

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries







MAIN PRODUCTS		DESCRIPTION	END-MARKETS
SPECIALTY CHEMICALS	CREAMINO®	A feed additive for broilers and pigs	Feed additive
	Creapure®	Premium brand for creatine monohydrate as a food supplement in sports nutrition	Food supplements
	LIVADUR	Dietary supplement with pure creatine	Food supplements
	Dormex®	Plant growth regulator used in fruit production	Agriculture
	BREATHRU'S 301	Additive for plant protection formulations	Agriculture
	Sitofex®	Plant growth regulator used in fruit production	Agriculture
	Alzogur®	Biocide for the prevention of diseases in animal production	Agriculture
	Silzot HQ	Silicon nitride powder for ceramic applications	Ceramics
	Bioselect®	Highly purified form of guanidine salts	Pharmaceuticals / API
	Cyanamide	An organic compound widely used in agriculture and pharmaceuticals	Agriculture and pharmaceuticals
	DYHARD®	Hardeners and accelerators in powder, paste and liquid form	Hardener & Accelerator Systems for Composite Materials
	Thiourea	Various applications incl. flotation agents and pharmaceutical raw materials	Mining and pharmaceuticals
	Nitroguanidine	Intermediates for agrochemical products	Various

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



	MAIN PRODUCTS	DESCRIPTION	END-MARKETS
BASICS & INTERMEDIATES	 CaD [®]	Calcium carbide-based mixtures for hot metal desulphurization	Steel industry
	Guanidine Salts	Fuel for airbags, key production of the intermediate product	Automotive
	Dicyandiamide	Versatile intermediate in various markets including the pharmaceutical industry	Pharmaceutical Agriculture
	 NITRALZ [®]	Business fields in color, agro and pharmaceutical applications	Pigments Pharmaceutical
	 Eminex [®]	Reduction of methane emissions during storage of manure	Agriculture
	 Perlka [®]	Special calcium cyanamide multi-effect fertilizer	Agriculture
OTHER & HOLDING	Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, MBCC Group, Firmenich, Aramark, VIActiv)		
	Site services		
	Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments		


KEY SHARE DATA

Share Details as of October 24, 2022



SHARES OUTSTANDING	10,176,335 including 40,581 shares held by Alzchem Group AG
LAST CLOSING PRICE	EUR 15.00
MARKET CAPITALIZATION	EUR 152.6 m
TICKER	ACT
WKN	A2YNT3
ISIN	DE000A2YNT30
LISTING	Frankfurt Stock Exchange – Prime Standard
DESIGNATED SPONSOR	Baader Bank AG Oddo Seydler Bank AG

SHAREHOLDER STRUCTURE



As of October 2022. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the “Guide to the DAX Equity Indices, i.e. considering the number of 40,581 own shares currently held by the company.”